In the FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial, evolocumab significantly reduced LDL-C levels by 15% for patients with atherosclerotic CVD and LDL-C > 70 mg/dL on statin therapy (HR 0.85; 95% CI, 0.79–0.92; P < 0.001) the risk of the primary endpoint (a composite of CV death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) and by 20% (HR 0.80; 95% CI, 0.73–0.88; P < 0.001) the risk of the secondary endpoint (a composite of CV death, MI, or stroke) after a median follow-up of 2.2 years [125]. This evidence concerns the gene PCSK9 and stroke disorder.